Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Clin Cancer Res. 2010 Sep 28;16(19):4779–4788. doi: 10.1158/1078-0432.CCR-10-1818

Figure 5. Activity of Gamitrinib in an orthotopic model of bone metastatic prostate cancer.

Figure 5

A, CB17 SCID/beige mice injected in the tibiae with PC3 cells were treated with G-TPP or vehicle (DMSO), and limbs of representative animals in each group (#) were analyzed by µCT. B, Percent change in bone volume (BV)/total volume (TV) ratio in individual animals (top) or groups (middle) treated with DMSO or G-TPP, as determined by µCT reconstruction of bone lesions. Bottom, percent BV of tibial tumor limb (TT) or contralateral tibia (CT). Mean±SEM of individual determinations. C, PC3 cells were treated with G-TPP or 17-AAG for the indicated time intervals, and analyzed by Western blotting.